Leonhardt Ventures LLC has announced the development of E-Stent™, a wireless bioelectric protein-expression stent system designed to activate or inhibit specific regenerative proteins directly from vessel walls and surrounding tissues. The technology platform combines a next-generation implant with a wireless wearable harness that delivers controlled protein expressions to micro-coils embedded along the stent, with sizes ranging from micro-implants smaller than a pea to 28 mm aortic stents.
The company has granted exclusive licenses for the E-Stent™ platform across 29 specialized medical applications. Kidney regeneration will be handled by KidneyCell™, while brain health applications including stroke recovery and brain aneurysm treatment will be managed by CerebraCell™. Addiction treatment falls to AddictiStim™, and memory improvement applications for dementia and Alzheimer's treatment will be developed by MemoryStim™.
Other licensed applications include severe depression and anxiety treatment through DepressiStim™, heart regeneration via BioLeonhardt™, cancer treatment through CancerCell™, and sensory regeneration including hearing through Ear-Cell™ and vision via Eye-Cell™. Healthspan longevity and medical aesthetics applications will be developed by Lionheart Health.
The platform's significance lies in its ability to stimulate or inhibit a broad range of proteins through selective bioelectric signaling, including klotho, sestrins, sirtuins, apelin, LIM, CXCL5, tropoelastin, COL17A1, SDF1 (stem cell homing), PDGF, NANOG, RANK-L, BMP9, OPG, VEGF, S100a, HIF1a, BDNF, Sonic Hedgehog, TGFb, and FABp4 downregulation. These stimulations can direct stem cell homing, proliferation, and differentiation on demand, potentially improving circulation, restoring muscle strength, modulating inflammation and blood pressure, improving nerve connections, and restoring elasticity.
Vascular applications include limb salvage and peripheral artery disease treatment through Vascustim™ and aorta regeneration via AortaCell™. Neurological applications extend to spinal cord injury recovery through SpineStim™ and essential tremor treatment via TremorStim™. The platform also addresses organ regeneration including liver through LiverCell™ and pancreas regeneration for diabetes treatment via PancreaCell™.
Additional licensed applications include blood pressure control through PressureStim™, inflammation modulation via InStim™, bladder dysfunction recovery through BladderCell™, and breathing optimization via BreatheStim™. The technology also extends to dental applications through DentaCell™ and orthopedic applications including knee osteoarthritis via OrthoStim™.
Brian Lasater, CTO of Leonhardt Ventures LLC and Lionheart Health, Inc., stated that working prototypes are currently in testing and are controlling regenerative and healing protein expressions on demand enabled fully by wireless energy. The E-Stent™ platform represents an evolution of Leonhardt Ventures' previously announced KlothoImplant Bioelectric MicroImplant, expanding the same core capabilities into advanced vascular implant formats.
The development team at Lionheart Health, majority owned by Leonhardt Ventures LLC, was recently recognized by Medtech Outlook Magazine as Micro Implant Stimulator Development of the Year 2025. The company emphasizes that all products are still in clinical studies and not yet fully proven to be safe or effective.
